← Leaderboards
Lee S Rosen
University Of California Los Angeles
$1,658,128
Attributed
$1,658,128
Total exposure
8
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$1,658,128 · 8
By mechanism
M01$1,658,128 · 8
Top collaborators
No co-investigators on record.
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Jeffrey I Zink$4,550,823
- Andre Elias Nel$21,296,649
- Harvey R. Herschman$16,718,124
- Ichiro Nishimura$3,632,930
- Mo Kwan Kang$3,420,661
Others in their field
Top investigators on “Human Therapy Evaluation”
- Lawrence Corey · Fred Hutchinson Cancer Center$368,153,539
- David Heimbrook · Leidos Biomedical Research, Inc.$241,598,366
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$212,820,795
- Barbara Driver · Westat, Inc.$206,347,735
- Carol Nesel · Westat$188,148,170
- Constance Ann Benson · University Of California, San Diego$179,950,251
Research focus
Human Therapy EvaluationHuman SubjectClinical ResearchDrug Screening /EvaluationClinical Trial Phase INeoplasm /Cancer ChemotherapyAntineoplasticsOral AdministrationDrug Administration Rate /DurationDrug Adverse EffectCombination Cancer TherapyIntravenous AdministrationLeucovorinFluorouracilColorectal NeoplasmsMetastasisCarcinomaCytotoxicityDiarrheaDosageFarnesyl CompoundGemcitabineGuanine Nucleotide Binding ProteinInjection /Infusion
Grant awards (12)
RANDOMIZED, PLACEBO-CONTROLLED PHASE I TRIAL OF RHUKGF IN COLORECTAL CARCINOMA$207,266
M01 · FY2001 · RR
RANDOMIZED, PLACEBO-CONTROLLED PHASE I TRIAL OF RHUKGF IN COLORECTAL CARCINOMA$207,266
M01 · FY2001 · RR
PHASE I, DOSE-ESCALATING STUDY OF SU5416 IN PATIENTS$207,266
M01 · FY2001 · RR
PHASE I, DOSE-ESCALATING STUDY OF SU5416 IN PATIENTS$207,266
M01 · FY2001 · RR
IRINOTECAN &TAXOL IN ADVANCED MALIGNANCIES$207,266
M01 · FY2001 · RR
IRINOTECAN &TAXOL IN ADVANCED MALIGNANCIES$207,266
M01 · FY2001 · RR
CONTINUOUS ORAL ADMINISTRATION SCH 66336 &IV GEMCITABINE$207,266
M01 · FY2001 · RR
CONTINUOUS ORAL ADMINISTRATION SCH 66336 &IV GEMCITABINE$207,266
M01 · FY2001 · RR
PHASE I TRIAL OF FB642 ORAL DOSAGE IN SOLID TUMORS$0
M01 · FY2001 · RR
SU5416/5 FLUOROURACIL/LEUCOVORIN IN COLORECTAL NEOPLASM$0
M01 · FY2001 · RR
PHASE I TRIAL OF SU00668 VIA ORAL ADMINISTRATION IN ADVANCED NEOPLASMS$0
M01 · FY2001 · RR
PHASE I TRIAL OF FB642 FOR ADVANCED SOLID TUMORS$0
M01 · FY2001 · RR